TP53 and cancer: Interestingly, we observed that the Cep55wt/Tg;Trp53+/− mice succumbed to a broad spectrum of cancer development (spleen, liver, and lung) with reduced latency (median survival of 13.8 months; p < 0.0001) when compared to the Cep55wt/wt;Trp53+/− cohort (median survival of 21.6 months) (Fig. 2c, Supplementary Fig. 3B–F, Supplementary Table 1).